Thermo Fisher Scientific Inc. (TMO) Stock: Price, Forecast & Analyst Target
Thermo Fisher Scientific Inc. (TMO) — MoonshotScore 69/100 (Strong band), calculated Oct 16, 2026. Price $690.00 (-0.93%), as of the Oct 16, 2026 trading session; market cap $255B. Expected results Oct 21, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 62.75× (market value Oct 16, 2026; cash Jun 27, 2026) · expected results Oct 21, 2026
Thermo Fisher Scientific Inc. · TMO · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Thermo Fisher Scientific supplies the working infrastructure of modern science: reagents, instruments, laboratory products, diagnostics, and outsourced biopharmaceutical services. Service and consumables generate far more revenue than instruments, so the business depends less on occasional equipment purchases than its diagnostics classification suggests. The case now rests on whether improving growth and profit can endure while cash remains well below debt.
Price as of Oct 16, 2026
Key Statistics
MoonshotScore v2 · Thermo Fisher Scientific (TMO)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $11.99B (Q2 FY2026, quarter ended Jun 27, 2026)
- EPS beat 6 of 8
- expected results Oct 21, 2026
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 67 | Strong | |
| 68 | Strong | |
| 67 | Strong | |
| 68 | Strong | |
| 68 | Strong | |
| 69 | Strong |
The score moved from 68 in the stored Oct 15, 2026 snapshot to 69 in the current publication computed Oct 16, 2026 (+1); the largest pillar moves were Growth Durability +2 and Financial Safety -1.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $690.00 | |
| Change on the day | -0.93% | |
| 52-week range | $435.27–$704.00 | |
| Market capitalisation | $255B | |
| Price / earnings (trailing) | 36.64 | |
| Shares traded on the day | 2.10M | |
| Beta (volatility vs the S&P 500) | 0.88 | |
| Dividends per share (last 12 months) | $1.84 | |
| Dividend yield (last 12 months) | 0.27% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Our expectation for full year organic revenue growth has increased to about 4%, our guidance range remains 3% to 4%, and we now expect to deliver at the upper end of that range.
Marc Casper · Statement from
I'll take you through an overview of our second quarter results for the total company and then provide color on our four business segments and conclude with details on our updated guidance for the year.
James Meyer · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for Thermo Fisher Scientific (TMO): Bullish Lean
62/100 · B+Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
2 lenses, 2 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 16, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 18, 2026, except a card that shows its own read date.
Watch the TMO film — every key number, told as a short cinematic story
~2 min · open the film
What is Thermo Fisher Scientific (TMO), and what does it report?
Short answer · as of
Thermo Fisher serves pharmaceutical and biotechnology companies, clinical laboratories, hospitals, universities, governments, and industrial researchers.
Research dated 2026-09-12.
Thermo Fisher serves pharmaceutical and biotechnology companies, clinical laboratories, hospitals, universities, governments, and industrial researchers. Its portfolio spans biological reagents, genetic and bioproduction tools, analytical instruments, diagnostic assays, laboratory distribution, clinical research support, and drug-development and manufacturing services.
The reported revenue mix is organized around what customers buy: service, consumables, and instruments. Service and consumables are the dominant streams, which means reported sales capture recurring laboratory activity and outsourced development work as well as demand for scientific equipment.
What do the latest results show for Thermo Fisher Scientific (TMO)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $11.99B.
Research dated 2026-09-12.
The latest reported period showed sequential and year-over-year gains in revenue, gross profit, operating profit, net income, and diluted earnings. Operating cash flow also strengthened, while revenue and adjusted earnings exceeded market estimates again, extending a broad run of positive surprises.
Management raised its revenue and earnings outlook after what it described as strong operational performance and a better outlook for the remainder of the year. That explanation should be kept separate from the reported improvement: the statements show stronger sales, profits, and cash generation, while management also says its updated guidance already includes the expected effect of the pending microbiology divestiture.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $11.99B Jun 27, 2026
- Latest quarter · R&D
- $364.00M Jun 27, 2026
- Latest quarter · SG&A
- $1.91B Jun 27, 2026
- Latest quarter · FMP standardized operating result
- $2.09B Jun 27, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 27, 2026 | $11.99B | $364.00M | $1.91B | $2.09B |
| Mar 28, 2026 | $11.01B | $336.00M | $1.80B | $1.86B |
| Dec 31, 2025 | $12.21B | $357.00M | $2.35B | $2.30B |
| Sep 27, 2025 | $11.12B | $347.00M | $2.16B | $2.08B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $11.99B Jul 23, 2026
- Latest report · revenue estimate
- $11.71B Jul 23, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 23, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 23, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 23, 2026 | $11.99B | $11.71B | $6.0300 | $5.7200 |
| Apr 23, 2026 | $11.01B | $10.86B | $5.4400 | $5.2500 |
| Jan 29, 2026 | $12.21B | $11.95B | $6.5700 | $6.4500 |
| Oct 22, 2025 | $11.12B | $10.92B | $5.7900 | $5.5000 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $11.99B | $1.74B | $4.68 (diluted) |
| Q1 FY2026 | $11.01B | $1.65B | $4.43 (diluted) |
| Q4 FY2025 | $12.21B | $1.98B | $5.21 (diluted) |
| Q3 FY2025 | $11.12B | $1.62B | $4.27 (diluted) |
What are the financial strengths and risks for Thermo Fisher Scientific (TMO)?
Short answer
Cash and short-term investments were $4.06B at the Jun 27, 2026 balance-sheet date. Operating cash flow was $2.13B for the quarter ended Jun 27, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Thermo Fisher has remained profitable and generated positive operating cash flow throughout the displayed quarterly run, with operating cash flow consistently exceeding capital spending. Standard liquidity ratios also indicate that current and liquid assets cover corresponding short-term obligations.
The balance-sheet constraint is leverage rather than operating cash burn. Debt substantially exceeds cash and short-term investments, the cash position has declined across the displayed window despite a recent sequential recovery, and the market valuation assumes continued earnings and free-cash-flow delivery. A slowdown in laboratory consumption or outsourced biopharmaceutical activity would therefore pressure the largest revenue streams while leaving the debt load in place.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $2.13B Jun 27, 2026
- Previous quarter · operating cash flow
- $1.19B Mar 28, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 27, 2026 | $2.13B | −$450.00M |
| Mar 28, 2026 | $1.19B | −$376.00M |
| Dec 31, 2025 | $3.46B | −$465.00M |
| Sep 27, 2025 | $2.24B | −$404.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Thermo Fisher Scientific (TMO)?
Short answer · as of
The next earnings report is expected on Oct 21, 2026.
Research dated 2026-09-12.
The next earnings release needs to show whether revenue, operating profit, and cash generation retain their recent direction after a run of estimate beats. Service and consumables deserve particular attention because weakness there would reach much more of the revenue base than a change in instrument demand alone.
Completion of the microbiology divestiture is another concrete checkpoint. Management has already incorporated its expected effect into raised guidance, so the useful test is whether reported results remain consistent with that outlook as the portfolio changes.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Our expectation for full year organic revenue growth has increased to about 4%, our guidance range remains 3% to 4%, and we now expect to deliver at the upper end of that range.
Marc Casper ·
I'll take you through an overview of our second quarter results for the total company and then provide color on our four business segments and conclude with details on our updated guidance for the year.
James Meyer ·
Our updated guidance also incorporates the expected impact of the pending divestiture of our microbiology business, which we expect to close in the third quarter.
James Meyer ·
We are raising our guidance for the full year on the top and bottom line, reflecting our strong operational performance in the second quarter and increased outlook for the second half of the year and we're also incorporating the expected impact of the pending divestiture of our microbiology business.
Marc Casper ·
How does Thermo Fisher Scientific compare with its peers?
Short answer
Thermo Fisher Scientific's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Thermo Fisher is broader than a conventional diagnostics company and less dependent on instrument placements than a pure analytical-equipment vendor. It can sell the instrument, the consumables used around it, laboratory distribution and support, diagnostic products, and outsourced clinical or manufacturing services across the same research and healthcare ecosystem.
That breadth changes the comparison with narrower peers: demand arrives through recurring laboratory use and contracted services as well as capital-equipment purchases. The same breadth also spreads exposure across pharmaceutical, biotechnology, academic, governmental, clinical, environmental, and industrial customers rather than tying the company to a narrow testing market.
| Company | Price | Market value | Score |
|---|---|---|---|
| $560.36 Oct 16, 2026 | $44.2B | 93 5-pillar Oct 16, 2026 | |
| $262.54 Oct 16, 2026 | $39.6B | 93 5-pillar Oct 16, 2026 | |
| $38.83 Oct 16, 2026 | $171B | 91 5-pillar Oct 16, 2026 | |
| $165.41 Oct 16, 2026 | $257B | 87 5-pillar Oct 16, 2026 | |
| $432.49 Oct 16, 2026 | $234B | 87 5-pillar Oct 16, 2026 | |
| $150.62 Oct 16, 2026 | $286B | 86 5-pillar Oct 16, 2026 | |
| $172.97 Oct 16, 2026 | $48.8B | 85 5-pillar Oct 16, 2026 | |
| $1622.29 Oct 16, 2026 | $32.5B | 84 5-pillar Oct 16, 2026 | |
| $145.97 Oct 16, 2026 | $360B | 77 5-pillar Oct 16, 2026 | |
| $235.00 Oct 16, 2026 | $25.9B | 76 5-pillar Oct 16, 2026 | |
| $266.90 Oct 16, 2026 | $43.9B | 74 5-pillar Oct 16, 2026 | |
| $317.95 Oct 16, 2026 | $25.8B | 73 5-pillar Oct 16, 2026 | |
| Thermo Fisher Scientific (TMO) — this page | $690.00 | $255B | 69 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $520.00 – $750.00
- Consensus target
- $664.79
- Median target
- $685.00
Consensus record · Captured .
Measured against a quoted price of $690.00 (as of Oct 16, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 26, 2026
- Transactions
- 100
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 51
- Other transactions
- 49
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 91.4% Period end Jun 30, 2026
- Previous quarter · ownership
- 89.3% Prior to period end Jun 30, 2026
- Reporting holders
- 2,708 Period end Jun 30, 2026
- Previous quarter · holders
- 2,682 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 30,919,632 |
| Vanguard Capital Management LLC | 24,276,316 |
| State Street Corp | 16,825,879 |
| Fmr LLC | 14,084,488 |
| Morgan Stanley | 10,763,066 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Thermo Fisher Scientific (TMO)?
Common Questions About TMO (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why do Thermo Fisher consumables and services matter more than its instruments?
Consumables and service each contribute substantially more revenue than instruments. Thermo Fisher therefore participates in ongoing laboratory workflows and outsourced biopharmaceutical work, not merely in equipment replacement cycles.
How do Patheon and PPD change Thermo Fisher's business model?
Patheon and PPD extend Thermo Fisher beyond laboratory products into pharmaceutical manufacturing and clinical research support. Those activities make customer development programs a direct source of service revenue alongside product sales.
What does Thermo Fisher's pending microbiology divestiture change?
Management has already included the expected divestiture effect in its updated revenue and earnings guidance. Completion and the resulting change in business mix are therefore important checks on whether subsequent results remain aligned with that outlook.
Is Thermo Fisher's recent growth converting into cash?
Recent operating improvement has been accompanied by stronger cash generation, and operating cash flow has continued to cover capital spending. The cash balance has nevertheless been volatile and remains below its level at the beginning of the displayed window, partly separating operating performance from balance-sheet movement.
What is the TMO stock price today?
The last price recorded on this page for Thermo Fisher Scientific Inc. (TMO) is $690.00, as of the Oct 16, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TMO price target?
The analyst consensus price target for Thermo Fisher Scientific Inc. (TMO) is $664.79 (range $520.00 to $750.00, median $685.00), per FMP data captured Oct 17, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are TMO's next earnings?
The next earnings date listed on this page for Thermo Fisher Scientific Inc. (TMO) is Oct 21, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (84 figures)
The 84 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Marc Casper (Jul 23, 2026): Our expectation for full year organic revenue growth has increased to about 4%, our guidance range remains 3% to 4%, and we now expect to deliver at the upper end of that range. James Meyer (Jul 23, 2026): I'll take you through an overview of our second quarter results for the total company and then provide color on our four business segments and conclude with details on our updated guidance for the year. James Meyer (Jul 23, 2026): Our updated guidance also incorporates the expected impact of the pending divestiture of our microbiology business, which we expect to close in the third quarter. Marc Casper (Jul 23, 2026): We are raising our guidance for the full year on the top and bottom line, reflecting our strong operational performance in the second quarter and increased outlook for the second half of the year and we're also incorporating the expected impact of the pending divestiture of our microbiology business. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Waltham, MA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "168 Third Avenue, Waltham, MA, 02451, US". |
FMP — 73 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $690.00 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-17T20:04:55.015Z. | |
px.change | Change on the day | -0.93% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $255B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-16. FMP quote timestamp: 2026-10-16T20:00:02.000Z. Captured from FMP at 2026-10-17T20:04:53.736Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$6.49 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $11.99B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $435.27–$704.00 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 36.64 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.10M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.88 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Marc N. Casper | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 125,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $39.21B, net result $7.72B; FY2022 revenue $44.91B, net result $6.95B; FY2023 revenue $42.86B, net result $6.00B; FY2024 revenue $42.88B, net result $6.33B; FY2025 revenue $44.56B, net result $6.74B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Service $18.59B · Consumables $18.66B · Instruments $7.30B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 41.0% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-27.revenue_k | Revenue — period end 2026-06-27 | $11.99B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-27.rd_k | R&D — period end 2026-06-27 | $364.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-27.sga_k | SG&A — period end 2026-06-27 | $1.91B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-27.operating_result_k | FMP standardized operating result — period end 2026-06-27 | $2.09B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-28.revenue_k | Revenue — period end 2026-03-28 | $11.01B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-28.rd_k | R&D — period end 2026-03-28 | $336.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-28.sga_k | SG&A — period end 2026-03-28 | $1.80B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-28.operating_result_k | FMP standardized operating result — period end 2026-03-28 | $1.86B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $12.21B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $357.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $2.35B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $2.30B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-27.revenue_k | Revenue — period end 2025-09-27 | $11.12B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-27.rd_k | R&D — period end 2025-09-27 | $347.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-27.sga_k | SG&A — period end 2025-09-27 | $2.16B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-27.operating_result_k | FMP standardized operating result — period end 2025-09-27 | $2.08B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-23.revenue_actual | Revenue · reported — report date 2026-07-23 | $11.99B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.revenue_estimated | Revenue · estimate — report date 2026-07-23 | $11.71B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.eps_actual | EPS · reported — report date 2026-07-23 | $6.0300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.eps_estimated | EPS · estimate — report date 2026-07-23 | $5.7200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.revenue_actual | Revenue · reported — report date 2026-04-23 | $11.01B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.revenue_estimated | Revenue · estimate — report date 2026-04-23 | $10.86B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.eps_actual | EPS · reported — report date 2026-04-23 | $5.4400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.eps_estimated | EPS · estimate — report date 2026-04-23 | $5.2500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.revenue_actual | Revenue · reported — report date 2026-01-29 | $12.21B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.revenue_estimated | Revenue · estimate — report date 2026-01-29 | $11.95B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.eps_actual | EPS · reported — report date 2026-01-29 | $6.5700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.eps_estimated | EPS · estimate — report date 2026-01-29 | $6.4500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-22.revenue_actual | Revenue · reported — report date 2025-10-22 | $11.12B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-22.revenue_estimated | Revenue · estimate — report date 2025-10-22 | $10.92B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-22.eps_actual | EPS · reported — report date 2025-10-22 | $5.7900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-22.eps_estimated | EPS · estimate — report date 2025-10-22 | $5.5000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $4.06B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $2.13B | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-27. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $42.55B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 4.86× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-27.operating_cash_flow_m | Operating cash flow — period end 2026-06-27 | $2.13B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-28.operating_cash_flow_m | Operating cash flow — period end 2026-03-28 | $1.19B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-27.capex_m | Capital expenditure (reported) — period end 2026-06-27 | −$450.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-28.capex_m | Capital expenditure (reported) — period end 2026-03-28 | −$376.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $3.46B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$465.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-27.operating_cash_flow_m | Operating cash flow — period end 2025-09-27 | $2.24B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-27.capex_m | Capital expenditure (reported) — period end 2025-09-27 | −$404.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $520.00 – $750.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 17, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $664.79 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 17, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $685.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 17, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 100 transactions · 0 purchases, 51 sales, 49 other transactions · 12 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 26, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 91.4% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 89.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 2,708 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 2,682 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 30,919,632 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 24,276,316 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | State Street Corp — shares in provider snapshot | 16,825,879 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Fmr LLC — shares in provider snapshot | 14,084,488 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Morgan Stanley — shares in provider snapshot | 10,763,066 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 21, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-09-30 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-16 |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 62.75× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $4.06B at Jun 27, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-16. Balance-sheet reference date: 2026-06-27. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $1.84 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-17, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.27% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-23.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($11.99B) with the recorded estimate ($11.71B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-23.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($6.0300) with the recorded estimate ($5.7200) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 69 of 100 · Strong · pillars 82 / 30 / 45 / 46 / 91 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 68 (stored snapshot Oct 15, 2026) → 69 (current publication computed Oct 16, 2026) (+1) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-27. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-27.revenue_k,fin.q_table.depth.2026-06-27.rd_k,fin.q_table.depth.2026-06-27.sga_k,fin.q_table.depth.2026-06-27.operating_result_k,fin.q_table.depth.2026-03-28.revenue_k,fin.q_table.depth.2026-03-28.rd_k,fin.q_table.depth.2026-03-28.sga_k,fin.q_table.depth.2026-03-28.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-27.revenue_k,fin.q_table.depth.2025-09-27.rd_k,fin.q_table.depth.2025-09-27.sga_k,fin.q_table.depth.2025-09-27.operating_result_k. - Earnings-history note. Source series as of 2026-07-23. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-23.revenue_actual,earn.history.depth.2026-07-23.revenue_estimated,earn.history.depth.2026-07-23.revenue_actual.comparison,earn.history.depth.2026-07-23.eps_actual.comparison,earn.history.depth.2026-07-23.eps_actual,earn.history.depth.2026-07-23.eps_estimated,earn.history.depth.2026-04-23.revenue_actual,earn.history.depth.2026-04-23.revenue_estimated,earn.history.depth.2026-04-23.eps_actual,earn.history.depth.2026-04-23.eps_estimated,earn.history.depth.2026-01-29.revenue_actual,earn.history.depth.2026-01-29.revenue_estimated,earn.history.depth.2026-01-29.eps_actual,earn.history.depth.2026-01-29.eps_estimated,earn.history.depth.2025-10-22.revenue_actual,earn.history.depth.2025-10-22.revenue_estimated,earn.history.depth.2025-10-22.eps_actual,earn.history.depth.2025-10-22.eps_estimated. - Cash-flow note. Source series as of 2026-06-27. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-27.operating_cash_flow_m,fin.opcf.depth.2026-03-28.operating_cash_flow_m,fin.opcf.depth.2026-06-27.capex_m,fin.opcf.depth.2026-03-28.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-27.operating_cash_flow_m,fin.opcf.depth.2025-09-27.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research The company's SEC filings classify it under SIC 3829 — Measuring & Controlling Devices, NEC. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Service: $18.59B; Consumables: $18.66B; Instruments: $7.30B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Cash, investments and debt | Total debt: $42.55B; Liquidity basis: cash and short-term investments; Total liabilities: $60.49B; Cash and short-term investments: $4.06B; Cash and investments: $4.06B; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-23 | FMP | Financial Modeling Prep (FMP) earnings |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-23 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $4.06B; Cash and short-term investments: $4.06B; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-27 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-27; From: 2024-09-28; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $4.06B; Decline: $2.58B; Opening balance: $6.64B; Average change per period: $368.70M Change in cash, cash equivalents and short-term investments between the 2024-09-28 and 2026-06-27 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-27 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-27; Cash basis: cash and short-term investments; Net cash: -$38.48B; Total debt: $42.55B; Cash and investments: $4.06B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-27 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 1.18; Current ratio: 1.55; Debt to equity: 0.81; Net margin: 15.1%; Gross margin: 40.4%; Operating margin: 17.7%; Return on assets: 6.2%; Return on equity: 13.4% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-10-28; EPS estimate: $6.4 per share; Revenue estimate: $11.95B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
Data provided for informational purposes only.
ETFs that hold TMO
Funds in our ETF coverage that list TMO among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| VHT ETF | 3.33% | |
| ProShares - Ultra Health Care (RXL) | 2.40% | |
| Touchstone Climate Transition ETF (HEAT) | 2.29% |